CIK 0001936258 · Large accelerated filer
NewAmsterdam Pharma Co N.V.
Sign in to watch- Ticker
- NAMS
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- Netherlands
- Entity type
- operating
- Phone
- 35 206 2971
- Business address
- GOOIMEER 2-35, NARRDEN, Netherlands, 1411 DC
- Former names
- NewAmsterdam Pharma Co B.V.
Securities
- NAMS Ordinary Shares Nasdaq
- NAMSW Warrant Nasdaq
- Open-market buys, last 90 days
- $226,500
- in 1 filing
- Open-market sales, last 90 days
- $4,661,919
- in 3 filings, $4.6M under 10b5-1 plans
Net −$4,435,419. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-01-07 | Kooij Louise Frederika Chief Accounting Officer | Grant or award 10b5-1 | +12,000 | 24,353 | ||
| 2026-01-07 | Kooij Louise Frederika Chief Accounting Officer | Grant or award · Option (right to buy) 10b5-1 | +53,500 | 53,500 | ||
| 2026-01-07 | Somaiya Mayur Ian Chief Financial Officer | Grant or award 10b5-1 | +25,500 | 58,382 | ||
| 2026-01-07 | Somaiya Mayur Ian Chief Financial Officer | Grant or award · Option (right to buy) 10b5-1 | +115,000 | 115,000 | ||
| 2026-01-05 | Kastelein Johannes Jacob Pieter Chief Scientific Officer | Sale 10b5-1 | −6,000 | $33.25 | $200K | 73,481 |
| 2026-01-05 | Kooij Louise Frederika Chief Accounting Officer | Sale 10b5-1 | −2,647 | $33.25 | $88K | 12,353 |
| 2026-01-05 | Somaiya Mayur Ian Chief Financial Officer | Sale 10b5-1 | −5,118 | $33.25 | $170K | 32,882 |
| 2025-12-26 | Kooij Louise Frederika Chief Accounting Officer | Option exercise 10b5-1 | +38,872 | $10.00 | $389K | 53,872 |
| 2025-12-26 | Kooij Louise Frederika Chief Accounting Officer | Option exercise 10b5-1 | +5,000 | $10.90 | $55K | 58,872 |
| 2025-12-26 | Kooij Louise Frederika Chief Accounting Officer | Sale 10b5-1 | −43,872 | $35.30 | $1.5M | 15,000 |
| 2025-12-26 | Kooij Louise Frederika Chief Accounting Officer | Option exercise · Option (right to buy) 10b5-1 | −38,872 | 140,015 | ||
| 2025-12-26 | Kooij Louise Frederika Chief Accounting Officer | Option exercise · Option (right to buy) 10b5-1 | −5,000 | 218,134 | ||
| 2025-12-24 | Kooij Louise Frederika Chief Accounting Officer | Option exercise 10b5-1 | +26,011 | $10.00 | $260K | 41,011 |
| 2025-12-24 | Kooij Louise Frederika Chief Accounting Officer | Sale 10b5-1 | −26,011 | $35.68 | $928K | 15,000 |
| 2025-12-24 | Kooij Louise Frederika Chief Accounting Officer | Option exercise · Option (right to buy) 10b5-1 | −26,011 | 178,887 | ||
| 2025-12-23 | Kooij Louise Frederika Chief Accounting Officer | Option exercise 10b5-1 | +75,117 | $10.00 | $751K | 90,117 |
| 2025-12-23 | Kooij Louise Frederika Chief Accounting Officer | Sale 10b5-1 | −75,117 | $36.21 | $2.7M | 15,000 |
| 2025-12-23 | Kooij Louise Frederika Chief Accounting Officer | Option exercise · Option (right to buy) 10b5-1 | −75,117 | 204,898 | ||
| 2025-09-15 | Topper James N Director | Purchase | +660 | $23.70 | $16K | 3,028,524 |
| 2025-09-09 | Kooij Louise Frederika Chief Accounting Officer | Option exercise | +150,000 | $10.00 | $1.5M | 165,000 |
Page 6 of 15 · 300 trades